Revenue and Financial Performance - Revenue for Q2 2024 was 225.991million,adecreaseof24.1297.982 million in Q2 2023[2] - Total revenue for the three months ended June 30, 2024, was 225,991,adecreaseof24.1297,982 in the same period of 2023[10] - Capitated revenue increased to 64,005forthethreemonthsendedJune30,2024,comparedto49,764 in the prior year, representing a growth of 28.6%[10] - Total segment revenue for NeueCare for the three months ended June 30, 2024, was 76,985,anincreasefrom66,068 in the same period of 2023, representing a growth of 18.5%[12] - Total segment revenue for the six months ended June 30, 2024, was 321,613,downfrom476,801 in the same period of 2023, reflecting a decline of about 32.6%[13] Net Loss and Adjusted EBITDA - Net loss for Q2 2024 was (57.698)million,comparedtoanetlossof(88.627) million in Q2 2023, showing an improvement of 34.8%[2] - Net loss attributable to common shareholders for the three months ended June 30, 2024, was (71,390),comparedto(125,005) in the same period of 2023, reflecting a reduction of 42.9%[10] - Adjusted EBITDA for Q2 2024 was 3.962million,downfrom7.797 million in Q2 2023[2] - Adjusted EBITDA for the three months ended June 30, 2024, was 3,962,downfrom7,797 in the same period of 2023, a decline of approximately 49.1%[18] - NeueCare Adjusted EBITDA for the three months ended June 30, 2024, was 13,496,comparedto15,593 for the same period in 2023, a decrease of approximately 13.5%[21] - Adjusted EBITDA for the three months ended June 30, 2024, was (566,000),asignificantdecreasefrom2,996,000 in the prior year[22] - For the six months ended June 30, 2024, NeueSolutions reported an Adjusted EBITDA of (2,250,000),downfrom1,487,000 in the same period of 2023[22] Operating Expenses and Costs - Total operating expenses for the three months ended June 30, 2024, were 263,540,adecreaseof17.9321,396 in the same period of 2023[10] - Total operating expenses for the three months ended June 30, 2024, were 151,678,comparedto234,690 for the same period in 2023, a reduction of about 35.4%[13] - Medical costs for the three months ended June 30, 2024, were 177,681,downfrom245,160 in the same period of 2023, indicating a decrease of 27.5%[10] - Medical costs for the three months ended June 30, 2024, were 147,258,downfrom231,279 in the same period of 2023, indicating a decrease of approximately 36.3%[13] - The company incurred restructuring charges of 239forthethreemonthsendedJune30,2024,comparedto1,285 in the same period of 2023, reflecting a decrease of 81.4%[10] Assets and Liabilities - Total assets as of June 30, 2024, were 897.265million,downfrom1,225.480 million at the end of 2023[9] - Total liabilities decreased to 1,179.803millionfrom1,480.098 million at the end of 2023[9] Future Projections and Guidance - For 2024, revenue is expected to be approximately 950million,withNeueCarerevenueprojectedat320 million and NeueSolutions revenue at 640million[5]−AdjustedEBITDAguidancefor2024isbetween15 million and 25million[5]−Thecompanyaimstoreachthehighendofitsguidancerangeforconsumersservedbyyear−end2024[3]ConsumerMetrics−Value−basedconsumersserveddecreasedto364,000asofJune2024,downfrom373,000inJune2023[1]−Enablementserviceslivesincreasedsignificantlyto113,000from31,000year−over−year[1]CashFlowandOperatingActivities−Cashandcashequivalentsattheendoftheperiodwere261,458, down from 1,360,441attheendofthesameperiodin2023[11]−Thecompanyreportedanetcashusedinoperatingactivitiesof(77,148) for the six months ended June 30, 2024, compared to (724,026)inthesameperiodof2023,showingasignificantimprovement[11]SpecialItemsandAdjustments−Thecompanyrecognized11.4 million in intangible asset impairment expense due to operations classified as held-for-sale in the second quarter of 2024[22] - The non-cash compensation expense related to stock options and restricted stock units was estimated at $2.5 million for the three and six months ended June 30, 2024[22] - Restructuring and contract termination costs were incurred as part of a workforce reduction and early lease terminations, impacting the financial results[22] - The company plans to exclude the impact of held-for-sale operations from Adjusted EBITDA starting in the second quarter of 2024[22] - Transaction costs related to financing initiatives can vary significantly from period to period, affecting comparability of financial performance[22]